vs
Prestige Consumer Healthcare Inc.（PBH）とRevolve Group, Inc.（RVLV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revolve Group, Inc.の直近四半期売上が大きい（$324.4M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.1倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 5.7%、差は10.8%）。Revolve Group, Inc.の前年同期比売上増加率が高い（10.4% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $-13.3M）。過去8四半期でRevolve Group, Inc.の売上複合成長率が高い（9.5% vs 1.2%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
PBH vs RVLV — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $324.4M |
| 純利益 | $46.7M | $18.6M |
| 粗利率 | 55.5% | 53.3% |
| 営業利益率 | 29.1% | 6.3% |
| 純利益率 | 16.5% | 5.7% |
| 売上前年比 | -2.4% | 10.4% |
| 純利益前年比 | -23.5% | 50.4% |
| EPS（希薄化後） | $0.97 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $324.4M | ||
| Q3 25 | $274.1M | $295.6M | ||
| Q2 25 | $249.5M | $309.0M | ||
| Q1 25 | $296.5M | $296.7M | ||
| Q4 24 | $290.3M | $293.7M | ||
| Q3 24 | $283.8M | $283.1M | ||
| Q2 24 | $267.1M | $282.5M | ||
| Q1 24 | $277.0M | $270.6M |
| Q4 25 | $46.7M | $18.6M | ||
| Q3 25 | $42.2M | $21.2M | ||
| Q2 25 | $47.5M | $10.2M | ||
| Q1 25 | $50.1M | $11.8M | ||
| Q4 24 | $61.0M | $12.3M | ||
| Q3 24 | $54.4M | $11.0M | ||
| Q2 24 | $49.1M | $15.4M | ||
| Q1 24 | $49.5M | $10.9M |
| Q4 25 | 55.5% | 53.3% | ||
| Q3 25 | 55.3% | 54.6% | ||
| Q2 25 | 56.2% | 54.1% | ||
| Q1 25 | 57.3% | 52.0% | ||
| Q4 24 | 55.5% | 52.5% | ||
| Q3 24 | 55.5% | 51.2% | ||
| Q2 24 | 54.7% | 54.0% | ||
| Q1 24 | 54.8% | 52.3% |
| Q4 25 | 29.1% | 6.3% | ||
| Q3 25 | 29.1% | 7.1% | ||
| Q2 25 | 28.8% | 5.8% | ||
| Q1 25 | 29.8% | 5.0% | ||
| Q4 24 | 31.7% | 3.9% | ||
| Q3 24 | 29.7% | 5.0% | ||
| Q2 24 | 27.0% | 5.8% | ||
| Q1 24 | 29.7% | 3.4% |
| Q4 25 | 16.5% | 5.7% | ||
| Q3 25 | 15.4% | 7.2% | ||
| Q2 25 | 19.0% | 3.3% | ||
| Q1 25 | 16.9% | 4.0% | ||
| Q4 24 | 21.0% | 4.2% | ||
| Q3 24 | 19.2% | 3.9% | ||
| Q2 24 | 18.4% | 5.4% | ||
| Q1 24 | 17.9% | 4.0% |
| Q4 25 | $0.97 | $0.27 | ||
| Q3 25 | $0.86 | $0.29 | ||
| Q2 25 | $0.95 | $0.14 | ||
| Q1 25 | $1.00 | $0.16 | ||
| Q4 24 | $1.22 | $0.18 | ||
| Q3 24 | $1.09 | $0.15 | ||
| Q2 24 | $0.98 | $0.21 | ||
| Q1 24 | $0.98 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $292.3M |
| 総負債低いほど良い | $1.0B | — |
| 株主資本純資産 | $1.8B | $512.5M |
| 総資産 | $3.5B | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $292.3M | ||
| Q3 25 | $119.1M | $315.4M | ||
| Q2 25 | $139.5M | $310.7M | ||
| Q1 25 | $97.9M | $300.8M | ||
| Q4 24 | $50.9M | $256.6M | ||
| Q3 24 | $51.5M | $252.8M | ||
| Q2 24 | $34.3M | $244.7M | ||
| Q1 24 | $46.5M | $273.4M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | $512.5M | ||
| Q3 25 | $1.8B | $490.2M | ||
| Q2 25 | $1.9B | $468.6M | ||
| Q1 25 | $1.8B | $453.4M | ||
| Q4 24 | $1.8B | $437.8M | ||
| Q3 24 | $1.7B | $420.8M | ||
| Q2 24 | $1.7B | $405.8M | ||
| Q1 24 | $1.7B | $389.9M |
| Q4 25 | $3.5B | $765.0M | ||
| Q3 25 | $3.4B | $751.3M | ||
| Q2 25 | $3.4B | $722.9M | ||
| Q1 25 | $3.4B | $713.9M | ||
| Q4 24 | $3.3B | $665.5M | ||
| Q3 24 | $3.3B | $670.9M | ||
| Q2 24 | $3.3B | $657.8M | ||
| Q1 24 | $3.3B | $650.0M |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $-13.3M |
| FCFマージンFCF / 売上 | 26.6% | -4.1% |
| 設備投資強度設備投資 / 売上 | 1.1% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $-10.2M | ||
| Q3 25 | $57.5M | $11.8M | ||
| Q2 25 | $79.0M | $12.6M | ||
| Q1 25 | $61.8M | $45.1M | ||
| Q4 24 | $65.1M | $3.9M | ||
| Q3 24 | $69.8M | $9.1M | ||
| Q2 24 | $54.8M | $-24.7M | ||
| Q1 24 | $66.9M | $38.4M |
| Q4 25 | $75.3M | $-13.3M | ||
| Q3 25 | $55.4M | $7.5M | ||
| Q2 25 | $78.2M | $10.4M | ||
| Q1 25 | $58.4M | $43.4M | ||
| Q4 24 | $63.5M | $2.1M | ||
| Q3 24 | $67.8M | $8.0M | ||
| Q2 24 | $53.6M | $-25.7M | ||
| Q1 24 | $63.8M | $36.7M |
| Q4 25 | 26.6% | -4.1% | ||
| Q3 25 | 20.2% | 2.5% | ||
| Q2 25 | 31.3% | 3.4% | ||
| Q1 25 | 19.7% | 14.6% | ||
| Q4 24 | 21.9% | 0.7% | ||
| Q3 24 | 23.9% | 2.8% | ||
| Q2 24 | 20.1% | -9.1% | ||
| Q1 24 | 23.0% | 13.5% |
| Q4 25 | 1.1% | 1.0% | ||
| Q3 25 | 0.8% | 1.5% | ||
| Q2 25 | 0.3% | 0.7% | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 0.5% | 0.6% | ||
| Q3 24 | 0.7% | 0.4% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 1.1% | 0.6% |
| Q4 25 | 1.68× | -0.55× | ||
| Q3 25 | 1.36× | 0.56× | ||
| Q2 25 | 1.66× | 1.24× | ||
| Q1 25 | 1.23× | 3.82× | ||
| Q4 24 | 1.07× | 0.32× | ||
| Q3 24 | 1.28× | 0.83× | ||
| Q2 24 | 1.12× | -1.60× | ||
| Q1 24 | 1.35× | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
